Results 31 to 40 of about 4,418 (114)

The regulation and function of CD20: an “enigma” of B-cell biology and targeted therapy

Haematologica, 2020
The introduction of anti-CD20 monoclonal antibodies such as rituximab, ofatumumab, or obinutuzumab improved the therapy of B-cell malignancies even though the precise physiological role and regulation of CD20 remains unclear. Furthermore, CD20 expression
Gabriela Pavlasova, Marek Mraz
doaj   +1 more source

CD20 expression: A risk stratification factor for newly diagnosed multiple myeloma with t(11;14)

Frontiers in Oncology, 2022
ObjectiveTranslocation (11;14) is one of the most frequent recurrent cytogenetic abnormalities in multiple myeloma (MM), while its clinical prognostic value remains controversial. CD20 expression is uncommon in MM while strongly associated with t(11;14).
Yuan Jian, Zhiyao Zhang, Huixing Zhou, Guangzhong Yang, Chuanying Geng, Huijuan Wang, Wen Gao, Wenming Chen   +7 more
doaj   +1 more source

Change of CD20 Expression in Diffuse Large B-Cell Lymphoma Treated with Rituximab, an Anti-CD20 Monoclonal Antibody: A Study of the Osaka Lymphoma Study Group

Case Reports in Oncology, 2009
Change of CD20 expression was examined in cases of diffuse large B-cell lymphoma (DLBCL). CD20 expression after treatment with anti-CD20 antibody (rituximab, Rx) for DLBCL was examined in 23 cases who received serial biopsy by immunohistochemistry (IHC ...
Naoki Wada, Masaharu Kohara, Hiroyasu Ogawa, Haruo Sugiyama, Shirou Fukuhara, Yoichi Tatsumi, Akihisa Kanamaru, Masayuki Hino, Yuzuru Kanakura, Eiichi Morii, Katsuyuki Aozasa   +10 more
doaj   +1 more source

Ocrelizumab Depletes CD20+ T Cells in Multiple Sclerosis Patients

Cells, 2018
Ocrelizumab, a humanized monoclonal anti-CD20 antibody, has shown pronounced effects in reduction of disease activity in multiple sclerosis (MS) patients and has recently been approved for the treatment of patients with relapsing MS (RMS) and primary ...
Stefan Gingele, Thais Langer Jacobus, Franz Felix Konen, Martin W. Hümmert, Kurt-Wolfram Sühs, Philipp Schwenkenbecher, Jonas Ahlbrecht, Nora Möhn, Lars H. Müschen, Lena Bönig, Sascha Alvermann, Reinhold E. Schmidt, Martin Stangel, Roland Jacobs, Thomas Skripuletz   +14 more
doaj   +1 more source

Characterization of the canine CD20 as a therapeutic target for comparative passive immunotherapy

Scientific Reports, 2022
Anti-CD20 therapies have revolutionized the treatment of B-cell malignancies. Despite these advances, relapsed and refractory disease remains a major treatment challenge.
Joana N. R. Dias, André Almeida, Ana S. André, Sandra I. Aguiar, Pedro Bule, Sara Nogueira, Soraia S. Oliveira, Belmira Carrapiço, Solange Gil, Luís Tavares, Frederico Aires-da-Silva   +10 more
doaj   +1 more source

HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies [PDF]

Blood, 2017
Key Points HDAC6 inhibition represents a novel strategy to improve the efficacy of anti-CD20 mAbs. HDAC6 inhibition increases CD20 levels by enhancing CD20 protein synthesis without affecting the gene expression.
Bobrowicz, Malgorzata, Dwojak, Michal, Pyrzynska, Beata, Stachura, Joanna, Muchowicz, Angelika, Berthel, Elise, Dalla-Venezia, Nicole, Kozikowski, Mieszko, Siernicka, Marta, Miazek, Nina, Zapala, Piotr, Domagala, Antoni, Bojarczuk, Kamil, Malenda, Agata, Barankiewicz, Joanna, Graczyk-Jarzynka, Agnieszka, Zagozdzon, Agnieszka, Gabrysiak, Magdalena, Diaz, Jean-Jacques, Karp, Marta, Lech-Maranda, Ewa, Firczuk, Malgorzata, Giannopoulos, Krzysztof, Efremov, Dimitar G, Laurenti, Luca, Baatout, Dunja, Frenzel, Lukas, Malinowska, Agata, Slabicki, Mikolaj, Zenz, Thorsten, Zerrouqi, Abdessamad, Golab, Jakub, Winiarska, Magdalena   +32 more
openaire   +2 more sources

Can quantitative monitoring of B cells evaluate the efficacy of Rituximab in primary CNS demyelinating disorders?

Annals of Medical Science and Research
Introduction: Rituximab (RTX), initially approved for various blood cancers, is additionally used for the management of primary central nervous system (CNS) demyelinating disorders.
Sayan Chatterjee, Peyalee Sarkar, Mitali Chatterjee, Biman Kanti Ray   +3 more
doaj   +1 more source

CD20-Positive B-Lymphocytes in the Reactive Tumor Microenvironment as an Independent Immunohistochemical Prognostic Factor in Nodular Sclerosis Classical Hodgkin Lymphoma

Клиническая онкогематология
Aim. To assess the prognostic value of CD20-positive B-lymphocytes in the reactive tumor microenvironment using histological specimens of lymph nodes from patients with nodular sclerosis classical Hodgkin lymphoma (cHL). Materials & Methods.
Maksim Sergeevich Minaev
doaj   +1 more source

HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20low expressing tumor cells that resist rituximab-mediated lysis

Haematologica, 2010
Background Incorporation of the chimeric CD20 monoclonal antibody rituximab in the treatment schedule of patients with non-Hodgkin’s lymphoma has significantly improved outcome. Despite this success, about half of the patients do not respond to treatment
Tom van Meerten, Henk Rozemuller, Samantha Hol, Petra Moerer, Mieke Zwart, Anton Hagenbeek, Wendy J.M. Mackus, Paul W.H.I. Parren, Jan G.J. van de Winkel, Saskia B. Ebeling, Anton C. Martens   +10 more
doaj   +1 more source

Prognostic Significance of Cancer Stem Cell Markers and Tumor Microenvironment Components for Assessing the Efficacy of Chemoradiotherapy in Patients with Locally Advanced rectal cancer

Инновационная медицина Кубани
Background: Despite the incorporation of neoadjuvant chemoradiotherapy into the standard treatment of locally advanced rectal cancer, significant variability in therapeutic response persists.
A. Yu. Georgieva, V. N. Bodnya, A. A. Verevkin   +2 more
doaj   +1 more source